ELREXFIO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Lithuania, Romania.

Active ingredients

The drug ELREXFIO contains one active pharmaceutical ingredient (API):

1	Elranatamab UNII L0HR9A577V - ELRANATAMAB
	Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.
	Read more about Elranatamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELREXFIO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
ELREXFIO Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX32		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX32

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3062933, 3062944
FR	Base de données publique des médicaments	65312065
LT	Valstybinė vaistų kontrolės tarnyba	1098434, 1098435
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70072001, W70072002
US	FDA, National Drug Code	0069-2522, 0069-4494, 63539-252